By R. Baldar. Nazarene Bible College.
Effect of switching to automated exchanges and use of DFX in iron load in SCD for 2 patients treated at University College London Hospitals toprol xl 25mg lowest price. The %HbS is maintained 40% more consistently with automated exchanges generic 25 mg toprol xl with mastercard. Introduction of DFX lowers SF while on manual exchanges and SF values close to normal ranges are achieved after switching to automated exchanges generic toprol xl 100mg otc. The trend in SF decreases toward the normal range only after introduction of DFX and automated exchange. A retrospective analysis of US health insurance claims, have accumulated high levels of iron before chelation is effec- including 106 SCD patients, found DFO utilization data suggest- tively introduced so that substantial negative balance is initially ing that the majority of patients are signiﬁcantly undertreated for required. Poor adherence to subcutaneous therapy is a serious iron overload compared with current guidelines. The accumulated experi- ity issues from overchelation, such as audiometric and retinal ence suggests that DFO acts on similar iron pools and has similar toxicity, are rare, being essentially those established with TM. Data obtained in 62 SCD There have been case reports of retinal toxicity with DFO at patients from a randomized trial of DFO versus DFX comparing doses usually considered safe with TM. Overchelation ( 40 LIC and ferritin trends and using variable dosing based on LIC10 mg/kg/d) can also result in decreased growth in children with have established the doses necessary to obtain iron balance. Very high doses of DFO should be avoided and have been Hematology 2013 453 associated with lung toxicity, which could in principle be Summary and recommendations mistaken for chest syndrome. Knowledge about the long-term consequences of iron overload and the beneﬁts of treatment has been gained largely from experience DFX has been developed relatively recently, so a greater number with TM. Because clear differences exist between SCD and other of patients have been assessed in formal trials ( 300 patients, forms of transfusional iron overload with respect to extrahepatic Table 2) than was the case historically with DFO. Since the iron distribution, more long-term information about the risks of iron introduction of this drug in 2007, it has become the most overload and the beneﬁts of treatment are required in SCD. A frequently used chelator in SCD in major centers in Europe. Prospective randomized data with DFO as the comparator minimize iron-mediated toxicity. Greater focus on the long-term has been obtained in 132 patients with prospective follow-up of 5 hepatic consequences of iron overload is also recommended in years in 63 patients. In monitoring of iron overload in SCD, the use of SF alone is year and signiﬁcant decrement in SF at 5 years, the mean dose particularly problematic and MRI monitoring of LIC is recom- increasing after 1 year. From the known transfusional iron mended to minimize over- or underchelation. Short- and medium- loading and the change in LIC, the dose required to obtain iron term response to chelation in SCD is affected by the transfusion balance depending on the iron-loading rate has been calculated regime, and a wider use of exchange rather than top-up transfusions and summarized in Table 1. In studies with DFX, the rate of iron will decrease the demands on chelation therapy in maintaining iron loading was not calculated in some cases and variability in overload at safe levels. Early studies also used conservative dosing starting Disclosures at 10 mg/kg, and higher doses of 20 mg/kg are usually necessary Conﬂict-of-interest disclosure: J. SF is a less sensitive maker of from Novartis; has consulted for Novartis, Shire, and Celgene; and response than LIC (Table 2), so serial LIC determination is has received honoraria from Novartis and Celgene. Off-label drug use: licensed combination of exchange transfusion with DFX can be particu- iron-chelating agents. Although labeling suggests ceasing DFX therapy when SF reaches 500 g/L, in practice, lower levels can be achieved Correspondence provided downward dose titration is practiced to achieve a “soft John Porter, MA, MD, FRCP, FRCPath, Department of Haematol- landing” (Figure 3). Tolerability in SCD has been similar to TM, ogy, University College London, Gower Street, London WC1E with mild to moderate gastrointestinal effects being the most 6BT, United Kingdom; Phone: 44 2076796224; Fax: 44 frequent. Mild stable increases in creatinine have been observed 2076796222; e-mail: j. A Cochrane References review before the publication of the 5-year follow-up study 1. Iron deﬁciency concluded that “deferasirox appears to be as effective as anaemia in sickle cell disorders in India.
Mobile phone technologies improve adherence to anti- retroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders order 100 mg toprol xl overnight delivery. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics purchase 100mg toprol xl overnight delivery, case reports and clinical management cheap 25mg toprol xl with mastercard. Getretener Quark wird breit, nicht stark: Was man von den “AIDS-Skeptikern” wirklich lernen kann. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and HIV drug resistance. Slain D, Amsden JR, Khakoo RA, Effect of high-dose vitamin C on the steady-state pharmacokinetics of the pro- tease inhibitor indinavir in healthy volunteers. Waning of virological benefits following directly administered art among drug users: results from a randomized, controlled trial. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor- based antiretroviral regimens with or without concurrent ritonavir. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. Adherence to antiretroviral therapy by HIV-infected patients. The impact of adherence on CD4 cell count responses among HIV-infected patients. All combinations currently used as initial regimens consist of two NRTIs plus either a PI, an NNRTI or an integrase inhibitor. Advantages and problems of these three strategies are outlined in Table 6. There are considerable differences between these strategies with respect to pill burden, food restrictions, side effects, resistance risk, drug interactions and the amount of available data in special patient populations. A third NRTI (triple nuke) is only used in exceptional cases and is only briefly men- tioned here. All other combinations such as NRTI-free regimens or dual therapies are currently (January 2015) not justified for use outside the framework of clinical studies. Large, sufficiently powered, randomized studies directly comparing these different strategies are listed in Table 6. It is obvious that the amount of data differs from agent to agent. Efavirenz-based regimens were the comparator arm in many studies. On the other hand, for nevirapine and especially for rilpivirine, data derived from class-comparing studies is much more limited. With regard to PIs, most studies were performed with atazanavir/r and darunavir/r. Lopinavir/r was mainly used in resource-poor settings. Some of these studies are also shown in the table as they may be relevant in special settings. In contrast, the validity of previous milestone trials such as Atlantic (van Leeuwen 2003) is considered limited today due to outdated combinations and are not mentioned here. In most of the trials, the antiviral potency of the regimens was comparable, meas- ured by the number of patients with viral load below the limit of detection. Although there were considerable differences with regard to tolerability and the rate of resist- ance mutations, these studies do not provide enough evidence to compromise one of the three drug classes. Note: The MERIT study is not mentioned here, as mara- viroc is not licensed for first-line therapy in Europe 188 ART NNRTIs versus PI/s In ACTG 5142, an advantage of efavirenz over lopinavir/r was observed after 96 weeks (12% more patients got to below 50 copies/ml).
But its clinical value is nonethe- less questionable when taking into account a chronic inflammation with HIV (Dhamidharka 2002 purchase 100 mg toprol xl with mastercard, Jaroszewicz 2006) purchase 25mg toprol xl overnight delivery. Clearance measurements can detect the “creatinine-blind” area of an early renal insufficiency faster and are particularly important when the kidney function is over-estimated due to lack of muscle mass discount toprol xl 50 mg otc. There are four procedures to determine GFR, of which the CKD-EPI formula has become established after scientific consideration, at least in mildly restricted renal insufficiency. In EuroSIDA, however, it was shown in more than 9,000 HIV+ patients and almost 125,000 measurements that both the Cockroft Gault and CKD-EPI for- mulas demonstrate renal insufficiency very well (Mocroft 2013). Cockroft Gault formula: •(140 – age) x kg body weight) divided by serum creatinine mg/dl x 0. MDRD formula (more precise, but requires additional laboratory data): •170 x Krea [mg/dl]-0. As an alternative2 186 x Krea [mg/dl]-1,154 x age-0203 x 1 (for women: x 0. Cystatin C clearance: •78 x 1/ CysC (mg/l) + 4 or 87 x 1/ CysC (mg/ ml) – 6. CKD-EPI formula (Levey 2009): •GFR = a x (serum creatinine /b)C x (0. The variable c adapts the formula to the serum creatinine value: women <0. Proteinuria The extent of proteinuria with loss of protein, the imbalance of serum protein frac- tions and residual kidney function with possible fluid retention all dictate edemas, loss of efficiency, susceptibility to infections, and hyperlipidemia. As with diabetes mellitus, microalbuminuria (Micral-Test in the urine) is an important indicator for the kidney and mortality due to cardiovascular events with HIV (Wyatt 2012). HIV+ patients with confirmed microalbuminemia are 25 times likelier to develop pro- teinuria, which, if it continues despite ART, is accompanied by a doubled risk of mor- tality (Wyatt 2012). HIV+ patients should be examined just as carefully for signs of kidney disease as diabetes patients. Clinically, a difference is made between nephrotic syndrome (loss of protein), acute nephritic syndrome (acantho- cytes as a sign of GN), rapid-progressive GN (loss of renal function within a few days), asymptomatic proteinuria or hematuria and chronic GN. These all need to be treated differently and require the collaboration of a nephrologist. HIV-associated nephropa- thy (HIV-AN) is a form of glomerulonephritis and is diagnosed in cases of nephrotic syndrome with edema, hypoalbuminemia, hyperlipidemia and proteinuria of more than 3. Urine sediment and sticks Alongside salts and crystals (e. The occurrence of proteinuria and erythrocyturia is pathognomonic for glomerulonephritis and, together with nephritic sediment, usually confirms the diagnosis. Under a polarizing microscope, a trained eye can easily identify the renal (glomerular) origin of the erythrocytes, on the basis of glomerularly deformed acanthocytes (erythro- cytes). More than five acanthocytes per field of vision is a significant sign for GN. Extensive erythrocyturia (bleeding) below the renal pelvis (tumor of the urinary tract collection system) can be excluded by sonography and, if necessary, by cystoscopy. A leukocyturia must first be clarified microbiologically (Uricult: midstream urine) in order to administer antibiotics according to the resistance situation, whereby a bacterial interstitial nephritis may also exist. In the case of a sterile leuko- cyturia, the possibility of urogenital tuberculosis should also be considered. However, it can also be the expression of an interstitial kidney disease (e. Glucosuria (with a normal blood sugar level/drop in the normal glucose level of the kidney) or phosphaturia are signs of a tubular disorder, such as can occur with medication (e.
Total mortality and rates of cardiovascular events were low and did not differ signiﬁ- that a drug with a well-known safety proﬁle proven toprol xl 25mg, a low cost purchase 25 mg toprol xl amex, and cantly between the 2 treatment groups cheap 50mg toprol xl mastercard. The associated risk reduction may be lower than that with the The AMPLIFY Extension study was a double blind trial in which oral anticoagulants but possibly associated with a lower risk for patients with VTE were randomized to receive 2 different doses of bleeding complications. Experimental treatment was given for a the treatment of VTE. In addition, patients who were receiving apixaban 2. The rates of major of Chest Physicians (ACCP) guidelines therefore recommend bleeding during the 12 month treatment period were 0. The rate over the other because no head-to-head comparison has been of death from any cause was 1. The study showed that, compared with placebo, both the 2. According to currently available evidence, only a minority of Clinically relevant nonmajor bleeding occurred in 2. The risk-beneﬁt for 1 year to prevent one episode of recurrent VTE (fatal or nonfatal) proﬁle of continued anticoagulation should be carefully discussed is 14. The results of this study could provide a rationale for with the patient (Figure 1). Anticoagulant therapy should be discontinued after the initial 3 to 6 Correspondence months in most patients who had the ﬁrst episode associated with Giancarlo Agnelli, MD, Internal and Cardiovascular Medicine, temporary risk factors. The duration of anticoagulant therapy in Stroke Unit, University of Perugia, Italy; Phone: 39-075-5786424; patients who had a ﬁrst episode of cancer-associated VTE should be Fax: 39-075-5782436; e-mail: agnellig@unipg. Anticoagulation could be discontin- References ued when the cancer has been completely cured. A population- based perspective of the hospital incidence and case-fatality The main achievement of recent trials for the extended treatment of rates of deep vein thrombosis and pulmonary embolism. The VTE with new or alternative agents is the widening of the Worcester DVT Study. The long term clinical availability of agents with improved safety proﬁles and different course of acute deep venous thrombosis. Predictors of comorbidities (ie, renal failure, gastric intolerance), and expected recurrence after deep vein thrombosis and pulmonary embo- adherence. However, the availability of new drugs should not lism: a population-based cohort study. Antithrombotic therapy for VTE disease: The case of aspirin for extended treatment of VTE is intriguing Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: because it offers a drug that is well known in terms of safety and side American College of Chest Physicians Evidence-Based Clini- effects; the lower effectiveness in terms of risk reduction was cal Practice Guidelines. A comparison of three months Conclusions of anticoagulation with extended anticoagulation for a ﬁrst Should clinical experience with the new agents conﬁrm the promis- episode of idiopathic venous thromboembolism. Schulman S, Beyth RJ, Kearon C, et al; American College of Because these agents avoid the need for laboratory monitoring and Chest Physicians. Hemorrhagic complications of anticoagulant dose adjustment, treatment of VTE will become easier for both and thrombolytic treatment: American College of Chest Physi- patients and clinicians. Clinicians should take time to educate cians Evidence-Based Clinical Practice Guidelines (8th Ed). Pulmonary embolism and deep Bayer HealthCare, Boehringer Ingelheim, Sanoﬁ, and Daiichi- vein thrombosis. Inﬂuence of preceding HealthCare, Pﬁzer, and Boehringer Ingelheim. Off-label drug use: length of anticoagulant treatment and initial presentation of None disclosed. Elevated D-dimer levels predict recurrence in trials. Agnelli G, Prandoni P, Becattini C, et al; Warfarin Optimal lant treatment in patients with cancer and venous thrombosis. Anticoagulation venous thromboembolism in patients with cancer (CLOT).
8 of 10 - Review by R. Baldar
Votes: 298 votes
Total customer reviews: 298